The objective of the present investigation was to study the potentiation of antitumor and antimetastatic activities of dl-α-difluoromethylornithine (DFMO) by inducers of interferon, namely, tilorone and polyriboinosinic:polyribocytidilic acid complex [poly(I)·poly(C)]. The results of this study indicate that these interferon inducers enhance the antitumor activity of DFMO against B16 melanoma and Lewis lung carcinoma in mice. In B16 melanoma, DFMO, tilorone, or poly(I)·poly(C), when administered alone, showed 85, 39, and 39% of inhibition of tumor growth, respectively. However, a combination of DFMO and tilorone or poly(I)·poly(C) resulted in 98 and 95% inhibition of growth, with about 20% of animals showing no detectable tumors. This potentiation appears to be related to the ability of the compounds to induce interferon, since an analogue of tilorone, MDL 10,842, neither induced interferon nor potentiated the antitumor activity of DFMO. The data also indicate that this combination is ...

ethyl 2-(fluoren-9-ylidenemethylamino)acetate - chemical structural formula, chemical names, chemical properties, synthesis references

You have a great website. Thanks for the work, good reference site. John H. Daniele Focosi ,mi at interhealth.info, wrote in message news:e794ccc8.0305072243.5e91f9ce at posting.google.com... , If you did refer to IFN-gamma try search for TLR ligands in Google , or visit , , http://digilander.libero.it/danielefocosi/immunityinnate.html#pattern , recognition receptors in innate immune , , (Copy the whole URL into your browser if the link doesnt work.) , Sincerely, , , Daniele , , , yangjing802 at sina.com (Ñî¾²) wrote in message news:,20030508013249.25977.qmail at sina.com,... , , I am a graduate student.Recently I am doing a paper about Interferon Inducers. However I only got limited information about these agents. would you please provide some help to me? , , , , Thanks , , , , Jing , , ______________________________________ , , , , =================================================================== , , --- ...

Peer Review Approval NA) Citation: EK Weisburger, Bioassay Program for Carcinogenic Hazards of Cancer Chemotherapeutic Agents. Cancer 40:1935-1949 (1977 ...

Peer Review Approval NA) Citation: EK Weisburger, Bioassay Program for Carcinogenic Hazards of Cancer Chemotherapeutic Agents. Cancer 40:1935-1949 (1977 ...

To our knowledge, maspin is the only serpin that sensitizes apoptosis, whereas all of the other serpins thus far implicated in apoptosis regulation appear to be antiapoptotic (17 , 32 , 33) . Thus, the existing literature offers little insight into the possible molecular mode of maspin action. The goal of the present study was to identify the specific target molecule(s), the modification of which by maspin sensitizes prostate and breast tumor cells toward potential cancer chemotherapeutic agents. By using multiple maspin-transfected cell lines in vitro, we obtained cellular, molecular, and biochemical evidence that supports a key role for Bax in maspin-mediated apoptosis sensitization. Although we may not have exhausted our search because of the ever-growing number of apoptosis regulators, our data seem sufficient to support our new hypothesis that the specific up-regulation of Bax, without changing Bcl-2, Bcl-xl, and Bak expression in maspin-transfected cells, may tip the balance of pro- versus ...

Background In recent years it has become evident that nonsteroidal anti-inflammatory drugs, in particular aspirin represent a potential class of cancer chemotherapeutic agents. Despite the wealth of...

DESCRIPTION WARNING TAXOL® (paclitaxel) Injection should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possibl...

Another interesting question is to what extent might the N methylation contribute to the bioavilability (the ADMET profile) in amide of small molecules rather than peptides ? For example, Tubulin-binding taxanes such as paclitaxel and docetaxel are important cancer chemotherapeutic agents. However, these drugs suffer from limitations such as poor aqueous solubility and oral bioavailability, emerging drug resistance, and the lack of blood-brain barrier permeability ...

7-[[(1R,4aR,6R,8aS)-5,5,8a-trimethyl-2-methylidene-6-oxidanyl-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]methoxy]-6,8-dimethoxy-chromen-2-one,7-(2-chloroethyl)-1,3-dimethyl-8-(phenylmethyl)purine-2,6-dione,7-methoxy-3-(4-methoxy-2-oxidanyl-phenyl)-2,3-dihydrochromen-4-one,7-(fluoren-9-ylidenemethyl)bicyclo[4.4.1]undeca-1,3,5,7,9-pentaene-2-carbaldehyde,7,12-dimethyl-9-(trifluoromethyl)benzo[a]anthracene,7,12-dimethyl-10-(trifluoromethyl)benzo[a]anthracene,7-[(3,4-dimethoxyphenyl)methyl]-6-methyl-7H-thieno[2,3-c]pyridine,7-azanyl-2-methyl-6-methylsulfanyl-isoquinoline-3,5,8-trione,7-[[4-[[4-[(6,8-disulfonaphthalen-2-yl)diazenyl]-2-methoxy-5-methyl-phenyl]carbamoylamino]-5-methoxy-2-methyl-phenyl]diazenyl]naphthalene-1,3-disulfonic acid,7,8,9,10-tetrahydrobenzo[a]pyren-10-ol,7-ethyl-2-methyl-1,3,4,8,9,9a-hexahydropyrazino[1,2-c]pyrimidin-6-one,7-phenyl-5-[(4-sulfophenyl)amino]benzo[a]phenazin-7-ium-6-sulfonic acid,7-[[1-methyl-4-[[1-methyl-4-[[1-methyl-5-[[1-methyl-5-[(4,6,8-trisulfonaphthalen-2-yl

Interferons: a viable alternative to antibiotics?. Richard S Müller. Consultant. As we all know the macrophage plays an essential role in initiation and maintenance of the immune response, and so in light of the increased incidence of antibiotic resistance, this article looks at the use of interferon treatments as an alternative to the use of antibiotics as a first line treatment.. Interferons are immunomodulatory molecules that show a wide range of applications due to their antiviral, antibacterial, antitumour and inflammatory activities. Whilst recombinant and natural interferons are among the most common biological therapeutics worldwide, interferon inducers are hardly mentioned in the West. With the increase in antibiotic resistance, is it time to revisit this alternative class of medications?. When interferon treatment was being developed in the Soviet Union, this was effectively overlooked in the West during the cold-war era due to its concentration on the development of vaccines. These ...

The design of self-assembled peptide-based structures for three-dimensional cell culture and tissue repair has been a key objective in biomaterials science for decades. in search of the simplest possible peptide system that can self-assemble, we discovered that combinations of di-peptides that are modified with aromatic stacking ligands could form nanometre-sized fibres when exposed to physiological conditions. For example, we demonstrated that a number of Fmoc (fluoren-9-ylmethyloxycarbonyl) modified di- and tri-peptides form highly ordered hydrogels via hydrogen-bonding and pi-pi interactions from the fluorenyl rings. These highly hydrated gels allowed for cell proliferation of chondrocytes in three dimensions [Jayawarna, Ali, Jowitt, Miller, Sal Gough and Ulijn (2006) Adv. Mater. 18, 611-614]. We demonstrated that fibrous architecture and physical properties of the resulting materials were dictated by the nature of the amino acid building blocks. Here, we report the self-assembly process of ...

Synthetic double-stranded ribopolynucleotides are inducers of interferon, a protein which increases the resistance of cells to virus attack.. This work describes the synthesis of poly (halogenated ribocytidylic acids) and their complex formation with both riboinosinic acid and deoxyriboinosinic acid. The RNA/RNA hybrids are potent interferon inducers with high thermal and nucleolytic stability, the DNA/RNA hybrids are, however, completely inactive . as inducers of interferon.. The synthesis and physical properties of poly (5-hydroxycytidylic . acid) are discussed. In basic solution this polymer undergoes a conformational change and can also bind magnesium ions in an unusual manner. The polymer does not hybridise with polyinosinic acid.. ...

The present study was designed to determine the effects of artemisinin (ARS) and its derivatives on human ovarian cancer cells, to evaluate their potential as novel chemotherapeutic agents used alone or in combination with a conventional cancer chemotherapeutic agent, and to investigate their underlying mechanisms of action. Human ovarian cancer cells (A2780 and OVCAR-3), and immortalized non-tumourigenic human ovarian surface epithelial cells (IOSE144), were exposed to four ARS compounds for cytotoxicity testing. The in vitro and in vivo antitumour effects and possible underlying mechanisms of action of dihydroartemisinin (DHA), the most effective compound, were further determined in ovarian cancer cells. ...These effects were also observed in in vivo ovarian A2780 and OVCAR-3 xenograft tumour models. In conclusion, ARS derivatives, particularly DHA, exhibit significant anticancer activity against ovarian cancer cells in vitro and in vivo, with minimal toxicity to non-tumourigenic human OSE ...

Gleostine® (lomustine) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.. Bone marrow suppression, notably thrombocytopenia and leukopenia, which may contribute to bleeding and overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of Gleostine® (see WARNINGS and ADVERSE REACTIONS).. Since the major toxicity is delayed bone marrow suppression, blood counts should be monitored weekly for at least 6 weeks after a dose (see ADVERSE REACTIONS). At the recommended dosage, courses of Gleostine® should not be given more frequently than every 6 weeks.. The bone marrow toxicity of Gleostine® is cumulative and therefore dosage adjustment must be considered on the basis of nadir blood counts from prior dose (see dosage adjustment table under DOSAGE AND ADMINISTRATION). more ,, ...

Over the past years natural products and/or their derivatives have continued to provide cancer chemotherapeutics. Glycosides derivatives of emodin are known to possess anticancer activities. An in silico study was carried out to evaluate emodin derivatives as inhibitors of Arylamine N-Acetyltransferase 2, Cyclooxygenase 2 and Topoisomerase 1 enzymes, predict their pharmacokinetics and explore their bonding modes. Molecular docking study suggested that D2, D5, D6 and D9 to be potent inhibitors of NAT2, while D8 was suggested to be a potent inhibitor of TOP1. Derivatives D2, D5, D6 and D9 bind to the same pocket with different binding conformation. Pharmacokinetic study suggested that selected emodin derivatives can be potential cancer chemotherapeutic agent. Physicochemical parameters such density, balaban index, surface tension, logP and molar reflectance correlated to compounds activity. These finding provides a potential strategy towards developing NAT2 and TOP1 inhibitors.

Dose-limiting toxicity of many cancer chemotherapeutic agents is peripheral neuropathy. Our data suggest that peripheral neuropathy may be reduced with the addition of glutamine in patients receiving high-dose paclitaxel as the first part of a tandem high-dose chemotherapy regimen. Glutamine appeared to reduce both the incidence and severity of symptoms previously observed with this dose. In addition, some of the signs of peripheral neuropathy were also reduced (vibration sense at the toes, interference with ADLs, gait, sensory deficits to pinprick) in patients who received glutamine compared with those who did not. Because a large proportion (38%) of the patients entered this trial with abnormal reflexes, it is not surprising that this parameter did not show any difference between the two groups. We opted to use the glutamine source cited in the original report because it is unknown whether all glutamine preparations are equivalent. The product that we used did not contain antioxidants because ...

Maria Tomasz was Distinguished Progressor Emerita of Chemistry and Biochemistry at Hunter College, City University of New York. She received her undergraduate education in chemistry at Lorand Eotvos University, Hungary and her PhD in organic chemistry at Columbia University. She joined the faculty at Hunter College in 1966, where she... read morethen spent the rest of her professional career. Her research focused on the molecular basis of the activity of cancer chemotherapeutic agents that target DNA covalently, and she published over 100 papers in this area. Her honors include a MERIT Award by the National Cancer Institute, a Japan Society for the Promotion of Science Invitational Fellowship, and she is a Fellow of the American Association for the Advancement of Science of the American Academy for the Advancement of Science. She sadly passed away in November 2016.. ...

Elevated serum levels of interferon-α among patients whose systemic lupus erythematosus (SLE) was in remission helped predict future disease flares, European researchers found.Among 254 SLE patients who were in remission, 26% had abnormally high serum levels of interferon-α at baseline, according to Alexis Mathian, MD, of Pitié-Salpêtrière Hospital in Paris, and colleagues.

Li Yw, Fakhara A, Shadan A, et al. Cancer Res August 1, 2005 65; 6934. doi: 10.1158/0008-5472.CAN-04-4604 Cancer chemotherapeutic strategies commonly require multiple agents. However, use of multiple agents contributes to added toxicity resulting in poor treatment outcome. Thus, combination chemotherapy must be optimized to increase tumor response and at the same time lower its […]. read more ...

Advanced cancer in the setting of liver dysfunction poses a dilemma for physicians, as many cancer chemotherapeutic agents undergo hepatic metabolism. Most cytotoxic drugs have a narrow therapeutic index, and the administration of chemotherapy to patients with liver impairment results in complicated safety issues. We present a concise review of cancer chemotherapy dosing in the setting of liver dysfunction. Although caution in treating all patients with hepatic failure is essential, the use of certain agents provokes greater concern than others. Continuous-infusion fluorouracil, capecitabine (Xeloda), mechlorethamine (Mustargen), cyclophosphamide, topotecan (Hycamtin), and oxaliplatin (Eloxatin) appear to be relatively well tolerated. On the contrary, taxanes, vinca alkaloids, irinotecan (Camptosar), and anthracyclines may cause unacceptable toxicity if administered to patients with poor hepatic function. For many anticancer agents, the paucity of data prohibits formal dosing recommendations, and most

Hartmann, J.T. Lipp, H.-P. Toxicity of platinum compounds. Expert Opin. Pharmacother; 2003. Jin Kim, Gi-Su Oh, Ai Hua Shen, Su Bin Lee, Khadka D, Pandit A, Hong-Seob So. Cisplatin induced kidney disfunction and perspectives on improving treatment strategies. The Korean Society of Electrolyte Metabolism. Electrolyte Blood Press. 2004; 12: 55-65. Brillet G, Deray G, Jacquiaud C et al. Long-term renal effect of cisplatin in man. Am J Nephrol. 1994; 14: 81-84. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003; 23: 460-464. Siddik, Zahid H.Mechanisms of action of cancer chemotherapeutic agents : dna-interactive alkylating agents and antitumour platinum-based drugs. Snedecor, G., Cochran, W., 1974. Ten Thousand Randomly Assorted Digits, in: Statistical Methods; 2002. Kawai Y, Nakao T, Kunimura N, et al. relationship of intracellular calcium and oxygen radicals to cisplatin-related renal cell injury. J Pharmacol Sci. 2006; 100: 65-72. Pabla N, Jiang M, Wei Q et al. Effects of ...

The 90 kDa heat shock proteins are proving to be extraordinary cancer chemotherapeutic targets as evidenced by the fact that more than 20 clinical trials are cu...

Chester, NJ Psychotherapist. Risa Simpson-Davis provides Marriage Counseling, Couples Counseling, Divorce Counseling, Child and Teen Therapy, Family Therapy, Depression Treatment, and Anxiety Treatment to Flanders, NJ, Long Valley, NJ, and Mendham, NJ